Neumora Therapeutics, Inc.
NMS: NMRALive Quote
📈 ZcoreAI Score
Our AI model analyzes Neumora Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NMRA Z-Score →About Neumora Therapeutics, Inc.
Healthcare
Biotechnology
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
📊 Fundamental Analysis
Neumora Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -121.2%, which indicates that capital utilization is currently under pressure.
At a current price of $2.04, NMRA currently sits at the 47th percentile of its 52-week range (Range: $0.61 - $3.65).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$371.36M
Trailing P/E
--
Forward P/E
-2.21
Beta (5Y)
3.12
52W High
$3.65
52W Low
$0.61
Avg Volume
1.33M
Day High
Day Low